Read by QxMD icon Read


Abby R Rosenberg, Miranda C Bradford, Elizabeth McCauley, J Randall Curtis, Joanne Wolfe, K Scott Baker, Joyce P Yi-Frazier
BACKGROUND: Adolescents and young adults (AYAs) with cancer are at risk for poor psychosocial outcomes. This study aimed to determine whether a novel intervention targeting resilience resources would improve patient-reported resilience, quality of life, and psychological distress. METHODS: In this parallel, phase 2 randomized controlled trial, English-speaking AYAs (12-25 years old) with cancer were randomized to the Promoting Resilience in Stress Management (PRISM) intervention or usual care (UC)...
September 19, 2018: Cancer
Jennifer W Mack
The Promoting Resilience in Stress Management intervention brings welcome news to adolescents and young adults with cancer, with an increase in resilience, improved cancer-related quality of life, and decreased overall distress among patients who participated in the intervention in comparison with controls. As the investigators think about their next steps, consideration of how best to expand this intervention to underserved populations should be a priority.
September 19, 2018: Cancer
Irene Prabhu Das, Melanie Baker, Cheryl Altice, Kathleen M Castro, Barbara Brandys, Sandra A Mitchell
Multidisciplinary treatment planning (MTP) is a process of engaging multiple disciplines to develop or refine the disease management plan. It is widely implemented in US cancer treatment settings and is considered to have favorable effects on both care quality and other outcomes. However, evidence reviews to date regarding MTP effectiveness have based their conclusions on studies conducted predominantly outside the United States. The authors conducted a systematic review of US-based studies to synthesize and critically appraise evidence of the effects of MTP on cancer care quality, health services outcomes, and survival...
September 14, 2018: Cancer
Scott F Huntington, Jessica R Hoag, Weiwei Zhu, Rong Wang, Amer M Zeidan, Smith Giri, Nikolai A Podoltsev, Steven D Gore, Xiaomei Ma, Cary P Gross, Amy J Davidoff
BACKGROUND: Although provider-level volume is frequently associated with outcomes in cancers requiring complex surgeries, whether similar relations exist for cancers treated primarily with systemic therapy is unknown. METHODS: Using a population-based cohort analysis of older adults diagnosed with diffuse large B cell lymphoma (DLBCL) during the years 2004-2011, we evaluated the association between oncologist volume and 4 clinical outcomes (receipt of any chemotherapy, receipt of an anthracycline-containing or equivalent regimen, early hospitalization, and overall survival)...
September 14, 2018: Cancer
Silvia Stacchiotti, Carlo Morosi, Salvatore Lo Vullo, Alessandra Casale, Elena Palassini, Anna Maria Frezza, Gabriella Dinoi, Antonella Messina, Alessandro Gronchi, Adalberto Cavalleri, Elisabetta Venturelli, Daniele Morelli, Silvana Pilotti, Paola Collini, Silvia Brich, Elena Tamborini, Luigi Mariani, Paolo G Casali
BACKGROUND: We present the results of an academic phase 2 study on imatinib plus everolimus in patients who have progressive advanced chordoma. METHODS: In January 2011, 43 adult chordoma patients were enrolled in the study and received imatinib 400 mg/day and everolimus 2.5 mg/day until progression or limiting toxicity. Eligible patients had progressed in the 6 months before study entry. PDGFRB, S6, and 4EBP1 expression and phosphorylation were evaluated by way of immunohistochemistry and/or western blotting...
September 14, 2018: Cancer
Maya F Ilowite, Hasan Al-Sayegh, Clement Ma, Veronica Dussel, Abby R Rosenberg, Chris Feudtner, Tammy I Kang, Joanne Wolfe, Kira Bona
BACKGROUND: Children with advanced cancer experience high symptom distress, which negatively impacts their health-related quality of life (HRQOL). To the authors' knowledge, the relationship between income and symptom distress and HRQOL is not well described. METHODS: The Pediatric Quality of Life and Symptoms Technology (PediQUEST) multisite clinical trial evaluated an electronic patient-reported outcome system to describe symptom distress and HRQOL in children with advanced cancer via repeated surveys...
September 14, 2018: Cancer
Raymond U Osarogiagbon
Multidisciplinary care is much advocated, little practiced. Prabhu Das and colleagues report on their comprehensive review of the published literature from the United States on the effects of this model of care delivery and demonstrate the dearth of high-quality studies of the process and outcome benefits of this structural model of cancer care delivery. See referenced original article on pages 1-11, this issue.
September 14, 2018: Cancer
Alisa M Goldstein, Kelsey C Stidd, Xiaohong R Yang, Mary C Fraser, Margaret A Tucker
BACKGROUND: In the United States, only approximately 0.4% of all melanomas are diagnosed in patients aged <20 years. To the authors' knowledge, melanoma in pediatric members of melanoma-prone families has not been fully investigated to date. The objective of the current study was to evaluate pediatric patients with melanoma with extensive follow-up in melanoma-prone families with and without cyclin-dependent kinase inhibitor 2A (CDKN2A) mutations. METHODS: For this non-population-based study, families were followed prospectively for up to 40 years...
September 12, 2018: Cancer
Ithaar H Derweesh, Stephen T Ryan, Zachary A Hamilton
No abstract text is available yet for this article.
September 12, 2018: Cancer
Benjamin T Ristau, Elizabeth A Handorf, David B Cahn, Alexander Kutikov, Robert G Uzzo, Marc C Smaldone
BACKGROUND: Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC). METHODS: The National Cancer Database was queried for patients with T1 and T2 RCC who underwent PN or RN from 2004 to 2014. Trends in surgery were evaluated using Cochran-Armitage tests...
September 12, 2018: Cancer
Navin R Changoor, Linda M Pak, Louis L Nguyen, Ronald Bleday, Quoc-Dien Trinh, Tracey Koehlmoos, Peter A Learn, Adil H Haider, Joel E Goldberg
BACKGROUND: Racial disparities in colorectal cancer (CRC) screening are frequently attributed to variations in insurance status. The objective of this study was to ascertain whether universal insurance would lead to more equitable utilization of CRC screening for black patients in comparison with white patients. METHODS: Claims data from TRICARE (insurance coverage for active, reserve, and retired members of the US Armed Services and their dependents) for 2007-2010 were queried for adults aged 50 years in 2007, and they were followed forward in time for 4 years (ages, 50-53 years) to identify their first lower endoscopy and/or fecal occult blood test (FOBT)...
September 12, 2018: Cancer
Austin J Parish, Vi Nguyen, Aaron M Goodman, Karthikeyan Murugesan, Garrett M Frampton, Razelle Kurzrock
BACKGROUND: Advances in deep sequencing technology have uncovered a widespread, protumorigenic role of guanine nucleotide-binding (G protein) α (GNA) subunits, particularly GNA subunits Gs (GNAS), Gq (GNAQ), and G11 (GNA11) (GNA*), in a diverse collection of malignancies. The objectives of the current study were: 1) to determine GNA* aberration status in a cohort of 1348 patients with cancer and 2) to examine tumor mutational burden, overall survival rates, and treatment outcomes in patients with GNA*-positive tumors versus those with tumors that had wild-type GNA*...
September 11, 2018: Cancer
Steven G DuBois, Theodore W Laetsch, Noah Federman, Brian K Turpin, Catherine M Albert, Ramamoorthy Nagasubramanian, Megan E Anderson, Jessica L Davis, Hope E Qamoos, Mark E Reynolds, Scott Cruickshank, Michael C Cox, Douglas S Hawkins, Leo Mascarenhas, Alberto S Pappo
BACKGROUND: The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were treated preoperatively with larotrectinib and underwent subsequent surgical resection. METHODS: A total of 24 children were treated on a pediatric phase 1 trial of larotrectinib (ClinicalTrials...
September 11, 2018: Cancer
Fang Fang Zhang, Melissa M Hudson, I-Chan Huang, Nickhill Bhakta, Kirsten K Ness, Tara M Brinkman, James Klosky, Lu Lu, Fan Chen, Rohit P Ojha, Jennifer Q Lanctot, Leslie L Robison, Kevin R Krull
BACKGROUND: Survivors of childhood cancer report poor health-related quality of life (HRQOL). Modifiable lifestyle factors such as nutrition and physical activity represent opportunities for interventions to improve HRQOL. METHODS: The authors examined the association between modifiable lifestyle factors and HRQOL among 2480 adult survivors of childhood cancer in the St. Jude Lifetime Cohort Study. Dietary intake, physical activity, cigarette smoking, and alcohol consumption were assessed through questionnaires...
September 11, 2018: Cancer
Meletios A Dimopoulos, Sagar Lonial, Keith A Betts, Clara Chen, Miriam L Zichlin, Alexander Brun, James E Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G Richardson
BACKGROUND: The randomized phase 3 ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab plus lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone (Ld) in relapsed/refractory multiple myeloma (RRMM), and to date, has the longest follow-up of any monoclonal antibody in patients with RRMM. METHODS: In this extended 4-year follow-up of the ELOQUENT-2 trial, the coprimary endpoints of progression-free survival (PFS) and overall response rate as well as the secondary endpoint of overall survival were assessed...
September 11, 2018: Cancer
Olaf P Geerse, Joshua R Lakin, Annette J Berendsen, Catherine M Alfano, Larissa Nekhlyudov
No abstract text is available yet for this article.
September 11, 2018: Cancer
Katja Leuteritz, Michael Friedrich, Annekathrin Sender, Erik Nowe, Yve Stoebel-Richter, Kristina Geue
BACKGROUND: Being diagnosed with and treated for cancer often has a strong impact on the life satisfaction (LS) of adolescents and young adults (AYAs). The current study investigated LS in AYA patients with cancer and determined associated factors. METHODS: Young patients (those aged 18-39 years at the time of diagnosis) with all malignant cancer sites and with a diagnosis made within the last 4 years were assessed. LS was measured at 2 measuring time points using the Questions on Life Satisfaction (FLZ-M)...
September 10, 2018: Cancer
Gregory S Cooper, Sanford D Markowitz, Zhengyi Chen, Missy Tuck, Joseph E Willis, Barry M Berger, Dean E Brenner, Li Li
BACKGROUND: Multitarget stool DNA (mt-sDNA) is an approved method for colon cancer screening that is especially relevant for patients who cannot undergo colonoscopy. Although the test performance has been evaluated in a large clinical trial, it was limited to a predominantly white population. Given differences in the epidemiology and biology of colon cancer in African American individuals, the authors sought to compare the performance of mt-sDNA between racial groups. METHODS: The authors prospectively identified patients aged ≥40 years who were referred for colonoscopy at an academic medical center and 2 satellite facilities...
September 7, 2018: Cancer
Paul D Brown, Vinai Gondi
The authors consider the importance of a careful, balanced review of therapeutic options with patients and the current understanding of the therapeutic ratio of whole-brain radiotherapy in patient populations with widespread intracranial disease. The goal of reviewing these options is to provide an unbiased discussion of the potential benefits and risks of whole-brain radiotherapy, particularly with regard to cognitive outcomes.
September 7, 2018: Cancer
Belle H de Rooij, Melissa S Y Thong, Janneke van Roij, Cynthia S Bonhof, Olga Husson, Nicole P M Ezendam
BACKGROUND: Threatening illness perceptions (IPs) have been associated with poorer health outcomes. However, to the authors' knowledge, it remains unclear whether threatening IPs that are consistent with disease severity are equally harmful. The aim of the current study was to: 1) identify subgroups of cancer survivors based on IP and prognosis; and 2) assess the health-related quality of life (HRQOL) and survival associated with these subgroups. METHODS: The authors used survey data from the population-based Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry, which were collected between 2008 and 2015 and included 2457 cancer survivors who were <5 years after their cancer diagnosis (colon, rectal, prostate, endometrial, or ovarian cancer or non-Hodgkin lymphoma)...
September 7, 2018: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"